Marizyme Statistics
Total Valuation
Marizyme has a market cap or net worth of 39,538. The enterprise value is 26.63 million.
| Market Cap | 39,538 |
| Enterprise Value | 26.63M |
Important Dates
The next estimated earnings date is Friday, August 15, 2025.
| Earnings Date | Aug 15, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Marizyme has 131.79 million shares outstanding. The number of shares has increased by 162.54% in one year.
| Current Share Class | 131.79M |
| Shares Outstanding | 131.79M |
| Shares Change (YoY) | +162.54% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 21.89% |
| Owned by Institutions (%) | n/a |
| Float | 72.35M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.22 |
| PB Ratio | -0.00 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -1.78 |
| EV / Sales | 145.21 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.03
| Current Ratio | 0.03 |
| Quick Ratio | 0.00 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -0.39 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -26.57% |
| Return on Invested Capital (ROIC) | -143.57% |
| Return on Capital Employed (ROCE) | 141.78% |
| Revenue Per Employee | 14,109 |
| Profits Per Employee | -1.15M |
| Employee Count | 13 |
| Asset Turnover | 0.01 |
| Inventory Turnover | 1.07 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -99.46% in the last 52 weeks. The beta is 0.78, so Marizyme's price volatility has been lower than the market average.
| Beta (5Y) | 0.78 |
| 52-Week Price Change | -99.46% |
| 50-Day Moving Average | 0.04 |
| 200-Day Moving Average | 0.12 |
| Relative Strength Index (RSI) | 41.92 |
| Average Volume (20 Days) | 21,466 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 0.00 |
Income Statement
In the last 12 months, Marizyme had revenue of 183,417 and -14.95 million in losses. Loss per share was -0.13.
| Revenue | 183,417 |
| Gross Profit | 116,048 |
| Operating Income | -12.36M |
| Pretax Income | -14.95M |
| Net Income | -14.95M |
| EBITDA | -11.82M |
| EBIT | -12.36M |
| Loss Per Share | -0.13 |
Balance Sheet
The company has 63,732 in cash and 26.66 million in debt, giving a net cash position of -26.59 million or -0.20 per share.
| Cash & Cash Equivalents | 63,732 |
| Total Debt | 26.66M |
| Net Cash | -26.59M |
| Net Cash Per Share | -0.20 |
| Equity (Book Value) | -15.54M |
| Book Value Per Share | -0.12 |
| Working Capital | -29.12M |
Cash Flow
| Operating Cash Flow | -3.74M |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
| Gross Margin | 63.27% |
| Operating Margin | -6,741.22% |
| Pretax Margin | -8,152.89% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Marizyme does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -162.54% |
| Shareholder Yield | n/a |
| Earnings Yield | -37,821.29% |
| FCF Yield | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on July 27, 2018. It was a reverse split with a ratio of 0.0344827.
| Last Split Date | Jul 27, 2018 |
| Split Type | Reverse |
| Split Ratio | 0.0344827 |
Scores
Marizyme has an Altman Z-Score of -14.63 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -14.63 |
| Piotroski F-Score | 3 |